In part three of the bladder cancer roundtable, Dr. Shilpa Gupta leads the panel on a discussion of the latest developments in bladder cancer treatments, focusing on antibody-drug conjugates and targeted therapies. The panel addresses the promising results of enfortumab vedotin combined with pembrolizumab and explores the role of HER2-targeted therapies, such as TDXD, in bladder cancer.
Emerging Targets in Bladder Cancer: EV Pembro, HER2, and ADC Therapies in Focus
By Shilpa Gupta, MD, Kala Sridhar, MD, Karine Tawagi, MD, Benjamin Garmezy, MD - Last Updated: December 30, 2024Post Tags:Roundtable MIBC
Related Posts
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.